ATE270884T1 - Langkettiger cyclohexenonalkohol zur behandlung von amyotropher lateraler sklerose - Google Patents

Langkettiger cyclohexenonalkohol zur behandlung von amyotropher lateraler sklerose

Info

Publication number
ATE270884T1
ATE270884T1 AT00902903T AT00902903T ATE270884T1 AT E270884 T1 ATE270884 T1 AT E270884T1 AT 00902903 T AT00902903 T AT 00902903T AT 00902903 T AT00902903 T AT 00902903T AT E270884 T1 ATE270884 T1 AT E270884T1
Authority
AT
Austria
Prior art keywords
sup
lateral sclerosis
amyotrophic lateral
active ingredient
cyclohexenone
Prior art date
Application number
AT00902903T
Other languages
English (en)
Inventor
Bang Luu
Gaby Schmitt
Florence Keyling
Celine Girlanda-Junges
Philippe Chabert
Jean-Philippe Loeffler
Bernadette Lutz-Bucher
De Aguilar Jose-Luis Gonzalez
Masashi Yamada
Yukie Suma
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Application granted granted Critical
Publication of ATE270884T1 publication Critical patent/ATE270884T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/713—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00902903T 1999-02-10 2000-02-10 Langkettiger cyclohexenonalkohol zur behandlung von amyotropher lateraler sklerose ATE270884T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3331299 1999-02-10
JP18054699A JP4469441B2 (ja) 1999-02-10 1999-06-25 神経変性疾患の予防又は治療薬
PCT/JP2000/000742 WO2000047199A1 (en) 1999-02-10 2000-02-10 Use of a cyclohexenone long-chain alcohol for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE270884T1 true ATE270884T1 (de) 2004-07-15

Family

ID=26371993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902903T ATE270884T1 (de) 1999-02-10 2000-02-10 Langkettiger cyclohexenonalkohol zur behandlung von amyotropher lateraler sklerose

Country Status (10)

Country Link
US (1) US7166642B1 (de)
EP (1) EP1150667B1 (de)
JP (1) JP4469441B2 (de)
AT (1) ATE270884T1 (de)
CA (1) CA2360246C (de)
DE (1) DE60012143T2 (de)
DK (1) DK1150667T3 (de)
ES (1) ES2223456T3 (de)
PT (1) PT1150667E (de)
WO (1) WO2000047199A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4861560B2 (ja) 2001-02-19 2012-01-25 株式会社明治 糖尿病合併症治療剤
WO2002094252A1 (en) * 2001-05-24 2002-11-28 Meiji Dairies Corporation Preventive or remedy for diseases caused by cerebrovascular disturbances
MXPA04005512A (es) * 2001-12-13 2004-12-06 Firmenich & Cie Compuestos para liberacion controlada de moleculas activas.
DE60319439T2 (de) * 2003-03-28 2008-06-19 Meiji Dairies Corp. Verfahren zur herstellung von langkettigen cyclohexenonalkolen
FR2860233B1 (fr) * 2003-09-26 2007-10-19 Univ Pasteur Composes promoteurs de la differenciation des precurseurs d'oligodendrocytes et modulateurs de l'activation microgliale, compositions et utilisations.
KR101194137B1 (ko) * 2004-10-13 2012-10-25 가부시키가이샤 메이지 ＳＴＡＴ３ 인산화 억제 및 Ｎｏｔｃｈ１ 발현 억제제
CA2589252C (en) * 2004-11-25 2012-12-04 Meiji Dairies Corporation Ameliorant for renal insufficiency
US20090069442A1 (en) * 2005-01-18 2009-03-12 Hirohito Shiomi Therapeutic Agent for Sensory Abnormality
US20080312336A1 (en) * 2005-05-26 2008-12-18 Keisuke Satoh Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder
ES2788598T3 (es) * 2012-11-21 2020-10-22 Golden Biotechnology Corp Métodos y composiciones para tratar enfermedades neurodegenerativas
RU2729186C2 (ru) * 2016-01-22 2020-08-05 Тайхо Фармасьютикал Ко., Лтд. Способ производства длинноцепочечного спирта циклогексенона высокой степени очистки
CN110187044B (zh) * 2019-01-17 2021-04-27 山东省农业科学院家禽研究所 一种银翘解毒口服液的质量检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044162A1 (fr) 1989-10-13 1991-04-14 Jacques Borg Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant
EP0593831B1 (de) 1992-11-18 1994-05-04 Medafor Langkettige Fettalkohole mit neurotropischer und gedächtnissfördernder Wirkung
US5843641A (en) 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US5786391A (en) 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
US5731354A (en) * 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
DE69811905T2 (de) 1997-08-13 2003-11-06 Meiji Milk Products Co. Ltd., Tokio/Tokyo Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel

Also Published As

Publication number Publication date
CA2360246A1 (en) 2000-08-17
DE60012143D1 (de) 2004-08-19
JP4469441B2 (ja) 2010-05-26
PT1150667E (pt) 2004-09-30
WO2000047199A1 (en) 2000-08-17
US7166642B1 (en) 2007-01-23
CA2360246C (en) 2008-04-15
ES2223456T3 (es) 2005-03-01
DK1150667T3 (da) 2004-08-30
JP2000297034A (ja) 2000-10-24
DE60012143T2 (de) 2004-11-25
EP1150667B1 (de) 2004-07-14
EP1150667A1 (de) 2001-11-07

Similar Documents

Publication Publication Date Title
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
DE69811905D1 (de) Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60012143D1 (de) Langkettiger cyclohexenonalkohol zur behandlung von amyotropher lateraler sklerose
HUP0400732A2 (hu) Gyógyászatilag hatékony uridin-észterek
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
AU6894800A (en) Caspase inhibitors and uses thereof
AU5343696A (en) Derivatives of succinamide and their use as metalloproteinas e inhibitor
NO20025510D0 (no) Tienodibenzoazulenforbindelser som tumor nekrose faktor inhibitorer
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE60216239T8 (de) Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie
ATE437636T1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
FI974444A0 (fi) N-hydroksiureayhdisteitä anti-inflammatorisina aineina
DE60238666D1 (de) Cyclohexenon derivate zur behandlung der diabetischen neuropathie
ATE273708T1 (de) Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
WO2000027378A3 (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
EP1325918A4 (de) Herzmuskelzellen-apoptose hemmstoffe und behandlung/vorbeugung von herzkrankheiten
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
KR950016739A (ko) 강박관념 질환 및 소모성 질환을 억제하는 방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1150667

Country of ref document: EP

REN Ceased due to non-payment of the annual fee